Siludi Pharmaceutical Co., Ltd. announced that the 3D189 global critical randomized phase III REGAL trial, a cooperative project between the company and SELLAS, achieved positive top-line results and successfully reached the predetermined main efficacy end point. The data showed that compared with the current best treatment plan selected by the researchers, 3D189 can reduce the risk of death by 41%, the risk ratio is 0.59, and the bilateral p-value is 0.035, which is statistically significant and has important clinical significance. The median overall survival time of patients in the 3D189 treatment group was 24 months, which was significantly superior to 14.7 months in the control group. In terms of safety, the overall tolerance was good, and there were no new safety signals. SELLAS plans to communicate with the US Food and Drug Administration to discuss an accelerated approval path, and plans to submit a biological product license application in the first half of 2027.

Zhitongcaijing · 2d ago
Siludi Pharmaceutical Co., Ltd. announced that the 3D189 global critical randomized phase III REGAL trial, a cooperative project between the company and SELLAS, achieved positive top-line results and successfully reached the predetermined main efficacy end point. The data showed that compared with the current best treatment plan selected by the researchers, 3D189 can reduce the risk of death by 41%, the risk ratio is 0.59, and the bilateral p-value is 0.035, which is statistically significant and has important clinical significance. The median overall survival time of patients in the 3D189 treatment group was 24 months, which was significantly superior to 14.7 months in the control group. In terms of safety, the overall tolerance was good, and there were no new safety signals. SELLAS plans to communicate with the US Food and Drug Administration to discuss an accelerated approval path, and plans to submit a biological product license application in the first half of 2027.